StreetAlpha.app
Home › Stocks › ADCT

ADC Therapeutics SA (ADCT)

$1.34
▲ +6.32%
LAST CLOSE · NOV 17

ADC Therapeutics develops cancer treatments, led by ZYNLONTA for certain lymphomas, and is based in Epalinges, Switzerland. It last closed at $1.34 on Nov 17, up 6.32% on the day.

AI Auto Pilots
Is ADCT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$84.9M
+12.8% vs a year ago
Net income
−$81.2M
−95.7% margin
EPS (diluted)
−$0.46
Free cash flow
−$100.5M
−118.5% margin
Valuation
Market cap
$171.7M
127.7M shares
P/E
–
No P/E while losing money
Price to sales
2.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$189.2M
At Sep 30
Shareholder equity
−$249.2M
Shares outstanding
127.7M
At Aug 3
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $33.9M$33.9MFY2021FY2022: $209.9M$209.9MFY2022FY2023: $69.6M$69.6MFY2023FY2024: $70.8M$70.8MFY2024FY2025: $81.4M$81.4MFY2025

From ADCT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated ADCT in the past 90 days.
Average 12-month target
No price targets on ADCT in the past 90 days.
Latest rating changes
GuggenheimMaintained
Aug 17Buy$5
RBC CapitalDowngrade
Jun 4Hold$2
DateFirmActionRatingPrice target
Aug 17GuggenheimMaintainedBuy$5
Jun 4RBC CapitalDowngradeHold$2
Loading…

Technical Analysis

ADCT · as of the Nov 17 close · updated after every close
Downtrend

The stock is 13% below its 20 day and 3% below its 50 day average. It is 75% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 45). The nearest support is the Pivot at $1.33, and the nearest resistance the swing high (Sep 3) at $1.37.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 12.1%/day
Key levels
$4.9852 week high+271.6%
$2.35200 day average+75.4%
$1.5220 day average+13.4%
$1.42Pivot R1+6.0%
$1.3950 day average+3.7%
$1.37Swing high (Sep 3)+2.2%
$1.34Last close
$1.33Pivot−0.7%
$1.28100 day average−4.5%
$1.26Pivot S1−6.0%
$1.21Swing low (Jul 10)−9.7%
$0.7852 week low−41.8%
Indicators
RSI (14)44.50Middle of its rangeNeutral
MACD-0.01Below its signal lineBearish
Stochastic9.0Near the bottom of its rangeOversold
ADX (14)21.4Weak trend
Williams %R-84.5Oversold below −80, overbought above −20Oversold
CCI (20)-160.4Oversold below −100, overbought above 100Oversold
Rate of change−13.8%Change over 10 sessionsBearish
ATR (14)$0.16Typical daily range, 12.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Below
What happened before, for ADCT

What happened before

See how ADCT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ADCT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ADCT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ADCT in the last 90 days.

Loading…

See today’s whale options flow across the market →

ADCT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●58 buying vs 51 selling
  • ▼Held by funds -8.7 pts
  • ▼Funds holding -4
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding110114−3.5%
In funds' top 1000–
Held by funds64.2%72.9%−8.7 pts
New / increased18 / 4027 / 43−17.1%
Reduced / sold out29 / 2229 / 30−13.6%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ADCT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ADCT is in one of them and how their past ADCT trades turned out.

ADCT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ADCT in an article yet. Here's the latest on the wider market.

ADCT Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Mar 22
Who traded ADCT · since 2025
Latest 1 filing
$1K – $15KTraded Feb 20, 2025Filed Mar 22, 2025
PersonTypeAmountTradedFiledDelay
Ashley MoodyR · FLSell$1K – $15KFeb 20, 2025Mar 22, 202530 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About ADC Therapeutics SA

ADC Therapeutics is a biopharmaceutical company based in Epalinges, Switzerland. It develops cancer treatments built on antibody drug conjugates, which link an antibody that targets cancer cells to a cell-killing payload. Its main product is ZYNLONTA, used for a type of lymphoma that has returned or stopped responding to earlier treatment, and partner Sobi handles much of its commercialization. Its customers include patients, the doctors who treat them, and the insurers and government programs that pay for care.

Headquarters
Epalinges, Switzerland